The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
The cardio-renal-metabolic connection: a review of the evidence
Open accessAbstract
Type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD), are recognized among the most disruptive public health issues of the current century. A large body of evidence from epidemiological and clinical research supports the existence of a strong interconnection between these conditions, such that the unifying term cardio-metabolic-renal (CMR) disease has been defined. This coexistence has remarkable epidemiological, pathophysiologic, and prognostic implications. The mechanisms of hyperglycemia-induced damage to the cardio-renal system are well validated, as are those that tie cardiac and renal disease together. Yet, it remains controversial how and to what extent CVD and CKD can promote metabolic dysregulation. The aim of this review is to recapitulate the epidemiology of the CMR connections; to discuss the well-established, as well as the putative and emerging mechanisms implicated in the interplay among these three entities; and to provide a pathophysiological background for an integrated therapeutic intervention aiming at interrupting this vicious crosstalks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, sustained weight reduction can help to defer the onset and reduce the progression of these co-morbidities [68-71].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 4×
“…Hypertension [132, 136] • HF [127, 134, 136] • CV death [128, 132] • CKD [127, 131, 132, 142] • ESKD [127] • Albuminuria [132, 142] GLP1 – RA • T2D [126, 131] • Overweight/obesity [126, 131] • Hypertension [126, 134, 137] • Atherosclerosis [131, 137] • Stroke [126, 134, 137] • CV death [131, 137]…”
BackgroundInfluentialBikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cited by
Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
Sebastian, S. A., Padda, I., & Johal, G. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102344 · Cited by 343
Li, W., Shen, C., Kong, W., Zhou, X., Fan, H., Zhang, Y., Liu, Z., & Zheng, L. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02352-6 · Cited by 234
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Cardiovascular-kidney-metabolic syndrome – An integrative review
Kittelson, K. S., Gasparotto, A., Fillmore, N., & Gomes, R. D. S. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.012 · Cited by 133
Yue, Y., Li, P., Sun, Z., Murayama, R., Li, Z., Hashimoto, K., & Zhang, Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02854-x · Cited by 113
Metadata
- Authors
- Marassi, M., & Fadini, G. P.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Fadini, Gian Paolo
- ORCID
- Fadini, Gian Paolo
- Venue
- Cardiovascular Diabetology
- Published
- 2023-07-31
- Volume
- 22
- Issue
- 1
- Pages
- 195-195
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC10391899
- OpenAlex
- W4385415147
- Cited by
- 386
- References
- 146
- Citations by year
- 2026: 173 · 2025: 156 · 2024: 54 · 2023: 3
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Italian Diabetes Society
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- type 2 diabetes, cardiovascular disease, chronic kidney disease, hyperglycemia, metabolic dysfunction, pathophysiology, prognosis
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Kidney, Metabolic Diseases, Renal Insufficiency, Chronic, Cardio-Renal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cardio-renal-metabolic connection: a review of the evidence. https://app.cochat.ai/papers/10.1186/s12933-023-01937-x
- The paper
- Marassi, M., & Fadini, G. P. (2023). The cardio-renal-metabolic connection: a review of the evidence. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-023-01937-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.